Over 1600 Total Lots Up For Auction at Four Locations - NJ Cleansweep 05/07, NJ Cleansweep 05/08, CA 05/09, CO 05/12

Joseph J. Cappello

Are You Dense, Inc. and Are You Dense Advocacy, Inc. announce executive director of both organizations
February 19, 2019
Women's Health
Joseph J. Cappello
Woodbury, Conn., Feb. 18, 20019 — The boards of the two nonprofits founded by the late Nancy M. Cappello, PhD, has announced today Joseph J. Cappello as their new executive director. For over a decade, Mr. Cappello has worked tirelessly, side-by-side as co-founder of the organizations with his wife, Dr. Cappello, earning him a unique perspective of the critical issue on adjunct screening for women with dense breast tissue.

"Duty compels me to carry on my wife's mission," declares Mr. Cappello. "Women have the right to know their breast density status, to have their complete breast health information. This vital piece of information was denied to Nancy when she was originally diagnosed with late stage 3c breast cancer in 2004. As a result of her hard work, 36 states currently mandate physicians to tell their patients their breast density status.

"Now, we are focusing our energies on getting legislation passed in the remaining 14 states" adds Mr. Cappello.
stats Advertisement
DOTmed text ad

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

stats
Science for decades has demonstrated that dense breast tissue is associated with a higher-than-average risk of breast cancer and that dense breast tissue can mask cancers on mammograms, making them impossible to detect. Adjunct screening to mammography, such as ultrasound and MRI, significantly increase detection of early cancers in dense breasts.

Dr. Cappello launched the legislative action of her organizations after being diagnosed with advanced-stage breast cancer in 2004 despite decades of normal mammography results. None of Dr. Cappello's physicians told her that she had dense breast tissue, which had hidden the growing cancer in her breast, and none advised her to get adjunct screening. Her home state of Connecticut passed the first bill in 2009.

Dr. Cappello passed away this past November due to complications from Myelodysplastic syndrome (MDS), a rare form of bone marrow cancer, and in some instances, may be associated with previous radiation and chemotherapy cancer treatments.

"I am empowered and honored to further the Are You Dense? mission," continues Mr. Cappello. "That being to reduce missed, delayed and advanced stage breast cancer by increasing access to early detection for women with dense breasts leading to reduced harms from aggressive treatments and better survival outcomes."

You Must Be Logged In To Post A Comment

 

advertisement

Women's Health Homepage

iCAD integrates mammo AI into Microsoft’s Precision Imaging Network
Bringing the ProFound Breast Health Suite to PowerScribe platform
SimonMed taps Lunit AI to enhance breast cancer detection services
Will incorporate Lunit software alongside Volpara Analytics to power its Personalized Breast Cancer Detection program
RadNet to acquire iCAD in $103 million all-stock deal focused on breast cancer AI
Will integrate software into DeepHealth
Amirix Imaging secures exclusive North American rights to Kailong mammo X-ray tubes
The LM33-T tube is marketed as a direct replacement for the Varex M113-T used in Hologic’s Dimensions and 3Dimensions systems
AI tool flags cardiovascular risk using mammograms, study shows
Assesses breast arterial calcification — calcium deposits visible on mammogram
GE HealthCare introduces AI-powered ABUS system for dense breast imaging
Invenia ABUS Premium integrates AI to enhance scan efficiency and image quality
Decline in breast cancer death rates has stalled for youngest and oldest women
Overall breast cancer mortality in US women declined 43.5% from 1990 to 2022
Mammo AI tool may help identify patients for supplemental breast MR
Researchers used ScreenPoint Medical's Transpara to demonstrate benefits
ScreenPoint Medical acquires Biomediq to enhance breast cancer risk assessment
Will integrate Biomediq’s risk assessment technology into Transpara solution
Study highlights benefits of contrast-enhanced mammo for women at high breast cancer risk
Detection rates align closely with outcomes reported for supplemental MR screening